Acrivon to Advance Two Clinical Programs in 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 13 2026
0mins
"2026 is an important catalyst year for Acrivon as we advance our two differentiated, AP3-guided clinical oncology programs towards key data read-outs," said Peter Blume-Jensen, chief executive officer, president and co-founder of Acrivon. "For ACR-368, we are increasingly focused on serous endometrial cancer, a disease with high unmet need contributing upwards of 50% of all endometrial cancer deaths every year. This focus is supported by the compelling clinical activity observed thus far and the enthusiastic endorsement by external KOLs. We are particularly excited by the prospect of rapid enrollment of the serous population in our Phase 2b study in the U.S. and EU given that there is no requirement for a biopsy. Given the accelerated enrollment, we are now planning to conduct a pre-specified simultaneous interim analysis of both Arms 3 and 4 in second half of 2026. In parallel, we continue advancing ACR-2316 which has shown exciting initial clinical activity in AP3-prioritized tumor types, including lung cancers which are traditionally not sensitive to WEE1 inhibitors. With cash runway expected into the third quarter of 2027, we believe we are well positioned to execute through multiple potential value-inflection milestones."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ACRV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ACRV
Wall Street analysts forecast ACRV stock price to rise
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 1.630
Low
7.00
Averages
10.50
High
19.00
Current: 1.630
Low
7.00
Averages
10.50
High
19.00
About ACRV
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision oncology medicines. It uses its precision Generative Phosphoproteomics platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a registrational Phase II trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore improve the clinical overall response rate (ORR) and has the potential to enable drug development. Its preclinical program, ACR-2316, is advancing in investigational new drug-enabling studies. It is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Acrivon Therapeutics to Participate in Oncology Innovation Summit
- Executive Participation: Acrivon Therapeutics' CEO Peter Blume-Jensen will participate in the TD Cowen 7th Annual Oncology Innovation Summit on May 26, 2026, showcasing the company's advancements in precision medicine, which is expected to enhance investor interest.
- Platform Strength: Acrivon's Generative Phosphoproteomics AP3 platform enables direct measurement of drug-regulated intracellular protein pathway activity states, driving rational drug design and clinical development, thereby enhancing the company's competitive edge in oncology drug development.
- Clinical Trial Progress: The company is advancing ACR-368 in a registrational intent Phase 2b study, which has received Fast Track designation from the FDA, indicating potential efficacy in endometrial cancer patients and presenting significant market opportunities.
- New Drug Development: Acrivon is also developing ACR-2316, a novel WEE1/PKMYT1 inhibitor, with initial data showing promising clinical activity across various solid tumor types, potentially transforming treatment strategies and improving patient survival rates.
See More
Acrivon Therapeutics Q1 Earnings Beat Expectations
- Earnings Performance: Acrivon Therapeutics reported a Q1 GAAP EPS of -$0.49, beating expectations by $0.03, indicating some improvement in financial management despite still being in a loss position.
- Financial Position: As of March 31, 2026, the company had $97.7 million in cash, cash equivalents, and investments, which, along with net proceeds from subsequent equity financing, is expected to fund operating expenses and capital expenditures into Q3 2027, ensuring short-term financial stability.
- Investor Engagement: Acrivon Therapeutics presented at the TD Cowen 46th Annual Health Care Conference and the ESGO 27th Annual Congress, demonstrating the company's proactive approach to engaging with investors and industry experts to enhance market awareness and potential financing opportunities.
- Historical Financial Data: The disclosure of historical financial data provides investors with a comprehensive financial background, aiding in the assessment of Acrivon's long-term investment value, even as the company continues to face profitability challenges.
See More
Acrivon Therapeutics Shows Strong Synergy in Cancer Treatments
- Preclinical Data Highlights: Acrivon Therapeutics' ACR-368 and ACR-2316 demonstrate strong synergy when combined with anti-PD-L1, supporting their potential as frontline clinical combinations that could redefine cancer treatment standards.
- Durable Immune Memory: The combination of ACR-2316 with anti-PD-L1 induces complete tumor regression and durable immune memory, indicating its significance in cancer immunotherapy and potentially offering patients longer-lasting efficacy.
- AACR Conference Presentation: Acrivon will present these findings at the 2026 AACR Annual Meeting, emphasizing the mechanistic basis derived from its AP3 platform, which may attract investor and partner interest, facilitating future clinical development.
- FDA Fast Track Designation: ACR-368 has received Fast Track designation from the FDA based on its potential efficacy in endometrial cancer patients, showcasing the company's strategic advantage and market prospects in precision medicine.
See More
Acrivon Therapeutics Q4 Earnings Miss Expectations
- Earnings Report: Acrivon Therapeutics reported a Q4 GAAP EPS of -$0.49, missing expectations by $0.01, indicating ongoing challenges in profitability that may affect investor confidence.
- Cash Reserves: As of December 31, 2025, the company had $118.6 million in cash, cash equivalents, and marketable securities, expected to fund operations into Q2 2027, suggesting adequate liquidity in the short term.
- Conference Presentations: Acrivon presented at the TD Cowen 46th Annual Health Care Conference and the ESGO 27th Annual Congress, aiming to enhance visibility among investors and the industry, potentially creating future financing opportunities.
- Market Attention: Seeking Alpha's Quant Rating on Acrivon Therapeutics reflects market scrutiny of its financial performance, prompting investors to closely monitor the company's future financial health and strategic adjustments.
See More
Acrivon Therapeutics Reports Promising Preclinical Results
- Clinical Trial Progress: Acrivon Therapeutics' ACR-368 demonstrates potent synergy with Topoisomerase 1 inhibitors in a registrational-intent Phase 2b study, indicating significant potential for enhancing treatment efficacy and improving patient outcomes in antibody-drug conjugates (ADCs).
- Immunotherapy Breakthrough: ACR-2316, when combined with anti-PD-L1, achieves complete and durable tumor regression in immunocompetent tumor mouse models, highlighting its potential value in immunotherapy and offering new treatment options for patients.
- AACR Conference Presentations: Acrivon will showcase three posters, including a late-breaking study, at the upcoming AACR Annual Meeting, further validating the unique advantages of its AP3 platform in identifying therapeutic candidates and combinations with significant clinical impact, potentially attracting more investor interest.
- FDA Fast Track Designation: ACR-368 has received Fast Track designation from the FDA based on its monotherapy potential in endometrial cancer patients, demonstrating the company's strategic positioning and competitiveness in the precision medicine market.
See More
FDA's Accelerated Approval Framework Drives Cancer Treatment Advances
- Clinical Survival Rate Improvement: A January 2026 analysis confirmed that drugs approved through the FDA's accelerated pathway improved progression-free survival in 65% of solid tumor indications, demonstrating significant clinical efficacy and driving clinical-stage oncology companies toward registration-directed study designs in high-unmet-need tumor types.
- Fast Track Designation: Oncolytics Biotech's cancer treatment pelareorep received FDA Fast Track designation for KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, achieving a 33% response rate in combination with standard chemotherapy, significantly higher than the 10% response rate with standard treatment, and a median survival of 27 months compared to 11.2 months with standard care.
- Substantial Market Potential: The second-line treatment market for KRAS-mutant microsatellite-stable colorectal cancer patients is estimated to be between $3 billion and $5 billion annually, with Oncolytics Biotech planning a controlled study to compare standard care versus standard care plus pelareorep, further validating its therapeutic advantage in this high-demand area.
- Team Expansion and Strategic Positioning: Oncolytics Biotech recently appointed two key executives to support its expansion plans, with CEO Jared Kelly emphasizing that the success of pelareorep in clinical trials will present significant market opportunities, particularly in cancer areas lacking effective treatment options.
See More
Acrivon Therapeutics to Participate in Oncology Innovation Summit
- Executive Participation: Acrivon Therapeutics' CEO Peter Blume-Jensen will participate in the TD Cowen 7th Annual Oncology Innovation Summit on May 26, 2026, showcasing the company's advancements in precision medicine, which is expected to enhance investor interest.
- Platform Strength: Acrivon's Generative Phosphoproteomics AP3 platform enables direct measurement of drug-regulated intracellular protein pathway activity states, driving rational drug design and clinical development, thereby enhancing the company's competitive edge in oncology drug development.
- Clinical Trial Progress: The company is advancing ACR-368 in a registrational intent Phase 2b study, which has received Fast Track designation from the FDA, indicating potential efficacy in endometrial cancer patients and presenting significant market opportunities.
- New Drug Development: Acrivon is also developing ACR-2316, a novel WEE1/PKMYT1 inhibitor, with initial data showing promising clinical activity across various solid tumor types, potentially transforming treatment strategies and improving patient survival rates.
See More
Acrivon Therapeutics Q1 Earnings Beat Expectations
- Earnings Performance: Acrivon Therapeutics reported a Q1 GAAP EPS of -$0.49, beating expectations by $0.03, indicating some improvement in financial management despite still being in a loss position.
- Financial Position: As of March 31, 2026, the company had $97.7 million in cash, cash equivalents, and investments, which, along with net proceeds from subsequent equity financing, is expected to fund operating expenses and capital expenditures into Q3 2027, ensuring short-term financial stability.
- Investor Engagement: Acrivon Therapeutics presented at the TD Cowen 46th Annual Health Care Conference and the ESGO 27th Annual Congress, demonstrating the company's proactive approach to engaging with investors and industry experts to enhance market awareness and potential financing opportunities.
- Historical Financial Data: The disclosure of historical financial data provides investors with a comprehensive financial background, aiding in the assessment of Acrivon's long-term investment value, even as the company continues to face profitability challenges.
See More
Acrivon Therapeutics Shows Strong Synergy in Cancer Treatments
- Preclinical Data Highlights: Acrivon Therapeutics' ACR-368 and ACR-2316 demonstrate strong synergy when combined with anti-PD-L1, supporting their potential as frontline clinical combinations that could redefine cancer treatment standards.
- Durable Immune Memory: The combination of ACR-2316 with anti-PD-L1 induces complete tumor regression and durable immune memory, indicating its significance in cancer immunotherapy and potentially offering patients longer-lasting efficacy.
- AACR Conference Presentation: Acrivon will present these findings at the 2026 AACR Annual Meeting, emphasizing the mechanistic basis derived from its AP3 platform, which may attract investor and partner interest, facilitating future clinical development.
- FDA Fast Track Designation: ACR-368 has received Fast Track designation from the FDA based on its potential efficacy in endometrial cancer patients, showcasing the company's strategic advantage and market prospects in precision medicine.
See More
Acrivon Therapeutics Q4 Earnings Miss Expectations
- Earnings Report: Acrivon Therapeutics reported a Q4 GAAP EPS of -$0.49, missing expectations by $0.01, indicating ongoing challenges in profitability that may affect investor confidence.
- Cash Reserves: As of December 31, 2025, the company had $118.6 million in cash, cash equivalents, and marketable securities, expected to fund operations into Q2 2027, suggesting adequate liquidity in the short term.
- Conference Presentations: Acrivon presented at the TD Cowen 46th Annual Health Care Conference and the ESGO 27th Annual Congress, aiming to enhance visibility among investors and the industry, potentially creating future financing opportunities.
- Market Attention: Seeking Alpha's Quant Rating on Acrivon Therapeutics reflects market scrutiny of its financial performance, prompting investors to closely monitor the company's future financial health and strategic adjustments.
See More
Acrivon Therapeutics Reports Promising Preclinical Results
- Clinical Trial Progress: Acrivon Therapeutics' ACR-368 demonstrates potent synergy with Topoisomerase 1 inhibitors in a registrational-intent Phase 2b study, indicating significant potential for enhancing treatment efficacy and improving patient outcomes in antibody-drug conjugates (ADCs).
- Immunotherapy Breakthrough: ACR-2316, when combined with anti-PD-L1, achieves complete and durable tumor regression in immunocompetent tumor mouse models, highlighting its potential value in immunotherapy and offering new treatment options for patients.
- AACR Conference Presentations: Acrivon will showcase three posters, including a late-breaking study, at the upcoming AACR Annual Meeting, further validating the unique advantages of its AP3 platform in identifying therapeutic candidates and combinations with significant clinical impact, potentially attracting more investor interest.
- FDA Fast Track Designation: ACR-368 has received Fast Track designation from the FDA based on its monotherapy potential in endometrial cancer patients, demonstrating the company's strategic positioning and competitiveness in the precision medicine market.
See More
FDA's Accelerated Approval Framework Drives Cancer Treatment Advances
- Clinical Survival Rate Improvement: A January 2026 analysis confirmed that drugs approved through the FDA's accelerated pathway improved progression-free survival in 65% of solid tumor indications, demonstrating significant clinical efficacy and driving clinical-stage oncology companies toward registration-directed study designs in high-unmet-need tumor types.
- Fast Track Designation: Oncolytics Biotech's cancer treatment pelareorep received FDA Fast Track designation for KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, achieving a 33% response rate in combination with standard chemotherapy, significantly higher than the 10% response rate with standard treatment, and a median survival of 27 months compared to 11.2 months with standard care.
- Substantial Market Potential: The second-line treatment market for KRAS-mutant microsatellite-stable colorectal cancer patients is estimated to be between $3 billion and $5 billion annually, with Oncolytics Biotech planning a controlled study to compare standard care versus standard care plus pelareorep, further validating its therapeutic advantage in this high-demand area.
- Team Expansion and Strategic Positioning: Oncolytics Biotech recently appointed two key executives to support its expansion plans, with CEO Jared Kelly emphasizing that the success of pelareorep in clinical trials will present significant market opportunities, particularly in cancer areas lacking effective treatment options.
See More
